Cargando…
The Effectiveness and Safety of Pharmaceutical-Grade Cannabidiol in the Treatment of Mastocytosis-Associated Pain: A Pilot Study
Mastocytosis patients often experience a number of symptoms, including mastocytosis-associated pain that is difficult to manage due to resistance to usual antalgic treatments and/or the patient’s poor tolerance. Mastocytosis patients display significantly higher levels of indoleamine-2,3-dioxygenase...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953706/ https://www.ncbi.nlm.nih.gov/pubmed/36831056 http://dx.doi.org/10.3390/biomedicines11020520 |
_version_ | 1784893944580014080 |
---|---|
author | Rossignol, Julien Hatton, Séverine Ridley, Ashley Hermine, Olivier Greco, Céline |
author_facet | Rossignol, Julien Hatton, Séverine Ridley, Ashley Hermine, Olivier Greco, Céline |
author_sort | Rossignol, Julien |
collection | PubMed |
description | Mastocytosis patients often experience a number of symptoms, including mastocytosis-associated pain that is difficult to manage due to resistance to usual antalgic treatments and/or the patient’s poor tolerance. Mastocytosis patients display significantly higher levels of indoleamine-2,3-dioxygenase-1 (IDO1) activity, leading to hyperactivation of the N-methyl-D-aspartate receptor. As cannabidiol (CBD) is known to inhibit IDO1′s enzymatic activity, we hypothesized that pharmaceutical-grade CBD is an effective treatment for mastocytosis-associated pain. Patients with non-advanced mastocytosis and refractory pain were eligible for inclusion in this observational pilot study. CBD was initiated at 50 mg/day and increased to a maximum of 900 mg/day. Pain was scored on a 0-to-10 numerical rating scale (NRS). A total of 44 patients were included over a 2-year period. The median dose of CBD prescribed was 300 mg/day (range: 50–900 mg/day). Elevated liver enzymes were observed in one patient. The mean ± standard deviation NRS pain score decreased significantly from 7.27 ± 1.35 before treatment to 3.78 ± 1.99 after 3 months of treatment (p < 0.0001). Fifteen patients (34%) were able to discontinue all their previous antalgic medications. CBD treatment might be a safe, effective treatment for mastocytosis-associated pain and its use requires confirmation in a randomized, controlled trial. |
format | Online Article Text |
id | pubmed-9953706 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99537062023-02-25 The Effectiveness and Safety of Pharmaceutical-Grade Cannabidiol in the Treatment of Mastocytosis-Associated Pain: A Pilot Study Rossignol, Julien Hatton, Séverine Ridley, Ashley Hermine, Olivier Greco, Céline Biomedicines Case Report Mastocytosis patients often experience a number of symptoms, including mastocytosis-associated pain that is difficult to manage due to resistance to usual antalgic treatments and/or the patient’s poor tolerance. Mastocytosis patients display significantly higher levels of indoleamine-2,3-dioxygenase-1 (IDO1) activity, leading to hyperactivation of the N-methyl-D-aspartate receptor. As cannabidiol (CBD) is known to inhibit IDO1′s enzymatic activity, we hypothesized that pharmaceutical-grade CBD is an effective treatment for mastocytosis-associated pain. Patients with non-advanced mastocytosis and refractory pain were eligible for inclusion in this observational pilot study. CBD was initiated at 50 mg/day and increased to a maximum of 900 mg/day. Pain was scored on a 0-to-10 numerical rating scale (NRS). A total of 44 patients were included over a 2-year period. The median dose of CBD prescribed was 300 mg/day (range: 50–900 mg/day). Elevated liver enzymes were observed in one patient. The mean ± standard deviation NRS pain score decreased significantly from 7.27 ± 1.35 before treatment to 3.78 ± 1.99 after 3 months of treatment (p < 0.0001). Fifteen patients (34%) were able to discontinue all their previous antalgic medications. CBD treatment might be a safe, effective treatment for mastocytosis-associated pain and its use requires confirmation in a randomized, controlled trial. MDPI 2023-02-10 /pmc/articles/PMC9953706/ /pubmed/36831056 http://dx.doi.org/10.3390/biomedicines11020520 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Rossignol, Julien Hatton, Séverine Ridley, Ashley Hermine, Olivier Greco, Céline The Effectiveness and Safety of Pharmaceutical-Grade Cannabidiol in the Treatment of Mastocytosis-Associated Pain: A Pilot Study |
title | The Effectiveness and Safety of Pharmaceutical-Grade Cannabidiol in the Treatment of Mastocytosis-Associated Pain: A Pilot Study |
title_full | The Effectiveness and Safety of Pharmaceutical-Grade Cannabidiol in the Treatment of Mastocytosis-Associated Pain: A Pilot Study |
title_fullStr | The Effectiveness and Safety of Pharmaceutical-Grade Cannabidiol in the Treatment of Mastocytosis-Associated Pain: A Pilot Study |
title_full_unstemmed | The Effectiveness and Safety of Pharmaceutical-Grade Cannabidiol in the Treatment of Mastocytosis-Associated Pain: A Pilot Study |
title_short | The Effectiveness and Safety of Pharmaceutical-Grade Cannabidiol in the Treatment of Mastocytosis-Associated Pain: A Pilot Study |
title_sort | effectiveness and safety of pharmaceutical-grade cannabidiol in the treatment of mastocytosis-associated pain: a pilot study |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953706/ https://www.ncbi.nlm.nih.gov/pubmed/36831056 http://dx.doi.org/10.3390/biomedicines11020520 |
work_keys_str_mv | AT rossignoljulien theeffectivenessandsafetyofpharmaceuticalgradecannabidiolinthetreatmentofmastocytosisassociatedpainapilotstudy AT hattonseverine theeffectivenessandsafetyofpharmaceuticalgradecannabidiolinthetreatmentofmastocytosisassociatedpainapilotstudy AT ridleyashley theeffectivenessandsafetyofpharmaceuticalgradecannabidiolinthetreatmentofmastocytosisassociatedpainapilotstudy AT hermineolivier theeffectivenessandsafetyofpharmaceuticalgradecannabidiolinthetreatmentofmastocytosisassociatedpainapilotstudy AT grecoceline theeffectivenessandsafetyofpharmaceuticalgradecannabidiolinthetreatmentofmastocytosisassociatedpainapilotstudy AT rossignoljulien effectivenessandsafetyofpharmaceuticalgradecannabidiolinthetreatmentofmastocytosisassociatedpainapilotstudy AT hattonseverine effectivenessandsafetyofpharmaceuticalgradecannabidiolinthetreatmentofmastocytosisassociatedpainapilotstudy AT ridleyashley effectivenessandsafetyofpharmaceuticalgradecannabidiolinthetreatmentofmastocytosisassociatedpainapilotstudy AT hermineolivier effectivenessandsafetyofpharmaceuticalgradecannabidiolinthetreatmentofmastocytosisassociatedpainapilotstudy AT grecoceline effectivenessandsafetyofpharmaceuticalgradecannabidiolinthetreatmentofmastocytosisassociatedpainapilotstudy |